Blood Microbiota Signature of Alzheimer's Disease

Alzheimer Disease Clinical Trial

— MICMALZ  

Official title:

Analysis of the Blood Signature of the Microbiota as a Diagnostic Marker of Alzheimer's Disease in the Early Stages of the Process: Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04841135
• Other study ID #: RECHMPL19_0041
• Status: Recruiting
• Phase: N/A
• Start date: June 3, 2021
• Est. completion date: January 2026

Study information

• Verified date: April 2023
• Source: University Hospital, Montpellier
• Contact: Karim BENNYS, MD, PhD
• Phone: +33 4 67 33 72 32
• Email: k-bennys[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to validate a difference in blood microbial signature between Alzheimer's patients and control subjects in order to propose potential innovative strategies

Description:

This is a pilot study only carried out in Montpellier, aimed at comparing AD patients with control subjects, including men / women aged between 50 and 85 years. The diagnosis of AD patients is based on international criteria. Metagenomics and proteomics will be used to determine the composition of the microbiota in whole blood and stools, but also the metabolomic profile in plasma, stool and the urines.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: January 2026
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

General criteria for AD and control groups:

• Male and/or female;
• Age between 50-85 years;
• Having given their free, informed, written consent, signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research);
• Patient benefiting from a social security scheme

AD group:

• Diagnosis of Alzheimer's disease according to the international ATN criteria of Albert et al, (1) who had a diagnostic lumbar puncture and CSF biomarker assay and brain imaging with analysis of hippocampal atrophy; topographic and pathophysiological markers must be positive to confirm the etiopathogenic diagnosis;
• Mild to moderate stage with MMSE score between 10 and 26 ;
• Symptomatic treatments specific to Alzheimer's disease (acetylcholinesterase inhibitors and memantine) and psychotropic treatments (anxiolytics, antidepressants, neuroleptics) are authorized but must be at fixed doses for more than 3 months ;

Control group:

• Patients seen in memory consultation for concern of having AD but for whom the workup is normal. These patients will have had a diagnostic lumbar puncture during the same memory consultation.

Neurotypical group criteria:

• Male and/or female ;
• Age between 18-35 years or between 50-85 years;
• Having given their free, informed, written and signed consent by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research);
• Patients without cognitive complaints seen in memory consultation but for whom the assessment is normal or young subjects recruited by advertisement. These participants will have an ex-post determination of plasma Aß and tau biomarkers. Exclusion criteria:

General criteria for AD and control groups:

• Absence of a family caregiver to complete the neuropsychological scales and questionnaires ;
• Patient living in a medical institution;
• Illiteracy or inability to complete the psycho-behavioral tests;
• Major physical or neurosensory problems likely to interfere with the tests;
• Contra-indication or refusal to perform the biological tests;
• Refusal to carry out neuropsychological tests.
• Refusal of stool collection
• Digestive neoplasia in progress or < 5 years old
• Digestive surgery with intestinal resection ;
• Presence of inflammatory bowel disease or other familial gastrointestinal pathology ;
• Chronic use of laxatives;
• Antibiotics taken within one month prior to inclusion;
• Short-term life-threatening conditions (active cancer, unstable heart failure, severe liver, kidney and respiratory failure);
• Chronic psychosis or psychotic episodes;
• Alcohol or drug addiction;
• Epilepsy and other non-degenerative diseases of the central nervous system
• Vitamin B12 deficiency and unsupplemented folic acid ;
• Untreated hypothyroidism;
• Patient deprived of liberty, by judicial or administrative decision;
• Major protected by law;
• Patient in a period of relative exclusion from another protocol;
• Refusal to participate in the protocol.

AD group :

• Insufficient clinical and paraclinical information for the diagnosis of AD;
• Genetic form of AD (known genetic mutation); Control and neurotypical groups: No specific non-inclusion criteria

Related Conditions & MeSH terms

• Alzheimer Disease
• Elderly With Normal Cognition

Intervention

Other:
• Multiomics quantification
One time blood, stool and urine samples will be taken.
• Polysomnography
Facultative polysomnography

Locations

Country	Name	City	State
France	Montpellier university hospital	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of bacterial 16S rDNA in stools	Concentration of bacterial 16S rDNA in stools	22 months
Secondary	Concentration of bacterial 16s DNA in blood	Concentration of bacterial 16s DNA in blood	22 months
Secondary	Multiomics microbiota signature in AD	Multiomics microbiota signature in AD	22 months